[Recombinant human erythropoietin (KRN5702) therapy for autologous blood transfusion in patients with rheumatoid arthritis undergoing joint replacement surgery--a multicenter phase II clinical trial]

MLA

I, Saikawa, et al. “[Recombinant Human Erythropoietin (KRN5702) Therapy for Autologous Blood Transfusion in Patients with Rheumatoid Arthritis Undergoing Joint Replacement Surgery--a Multicenter Phase II Clinical Trial].” Ryumachi. [Rheumatism], vol. 34, no. 3, June 1994. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........350ae4c6f3ea6d91c0b8b8b2598f7c00&authtype=sso&custid=ns315887.

APA

I, S., Y, S., T, H., H, T., S, I., K, T., H, I., R, O., M, K., & K, O. (1994). [Recombinant human erythropoietin (KRN5702) therapy for autologous blood transfusion in patients with rheumatoid arthritis undergoing joint replacement surgery--a multicenter phase II clinical trial]. Ryumachi. [Rheumatism], 34(3).

Chicago

I, Saikawa, Sugioka Y, Hotokebuchi T, Tsutsui H, Inaba S, Takagishi K, Iwata H, Ogawa R, Kondo M, and Ogata K. 1994. “[Recombinant Human Erythropoietin (KRN5702) Therapy for Autologous Blood Transfusion in Patients with Rheumatoid Arthritis Undergoing Joint Replacement Surgery--a Multicenter Phase II Clinical Trial].” Ryumachi. [Rheumatism] 34 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........350ae4c6f3ea6d91c0b8b8b2598f7c00&authtype=sso&custid=ns315887.